Skip to main content
Clinical Trials/NCT04798664
NCT04798664CompletedNot Applicable

Comparing Smoking Cessation Interventions Among Underserved Patients Referred for Lung Cancer Screening

Abramson Cancer Center at Penn Medicine5 sites in 1 country3,228 target enrollmentStarted: May 17, 2021Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
3,228
Locations
5
Primary Endpoint
Biochemically Confirmed Smoking Abstinence Sustained for 6 Months

Study Overview

Brief Summary

To compare the effectiveness of four interventions to promote sustained, biochemically confirmed smoking abstinence for 6 months among underserved smokers referred for lung cancer screening at four large U.S. health systems.

Detailed Description

We will conduct a 4-arm randomized trial comparing 4 interventions to promote sustained, biochemically confirmed smoking abstinence for 6 months among smokers in underserved demographic groups. The 3,200 participants to be enrolled will be current smokers who are Black, Hispanic, and/or have low socioeconomic status (defined as household income <200% of the federal poverty line or a high school education or less) or rural residence who are referred for low-dose computed tomography (LDCT) screening at 4 large health systems. All adult patients with LDCT orders will be further screened for eligibility. Eligible patients will enroll with opt-out consent and complete the study using the NIH-funded Way to Health online research portal. The primary outcome will be biochemically confirmed, sustained abstinence from smoking tobacco for 6 months following participants' selected quit dates. Relapse rates will be tracked at 12 months.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Current smoker (≥ 1 cigarettes per day, not including e-cigarettes)
  • Has a low-dose computed tomography (LDCT) scan ordered by their physician
  • Underserved, defined as one or more of the following: (a) Black, (b) Hispanic, (c) rural residence, or (d) low socioeconomic status (Defined as one or both of: high-school education or less, or household income <200% of the federal poverty line)
  • Able to receive study invitation and screening, by virtue of showing up to a radiology location affiliated with a participating health system for the LDCT, or having a valid email address or telephone number on file with the health system
  • Access to a cell phone with text messaging or the internet
  • Aged 18 years or older

Exclusion Criteria

  • No cell phone

Arms & Interventions

Basic Usual Care

No Intervention

Participants receive the usual care approach, Ask-Advise-Refer (AAR), which is a standard approach in which non-study clinicians ask smokers about their desire to quit smoking, advise them to quit, and provide informational resources such as hotlines, specialized clinics, or smoking cessation classes.

Enhanced Usual Care

Active Comparator

Participants receive the basic usual care of Ask-Advise-Refer as well as free access to nicotine replacement therapy (NRT) and/or reimbursement of up to $300 for any smoking cessation medications (varenicline/Chantix or bupropion/Zyban) prescribed by non-study clinicians.

Intervention: Removal of Financial Barriers (Behavioral)

Enhanced Usual Care plus Financial Incentives

Active Comparator

Participants receive all aspects of enhanced usual care plus an incentive plan in which they will be informed of their eligibility to earn $100, $200, and $300 if they submit negative tests for nicotine metabolites at 2 weeks, 3 month and 6 months following their quit date, respectively.

Intervention: Removal of Financial Barriers (Behavioral)

Enhanced Usual Care plus Financial Incentives

Active Comparator

Participants receive all aspects of enhanced usual care plus an incentive plan in which they will be informed of their eligibility to earn $100, $200, and $300 if they submit negative tests for nicotine metabolites at 2 weeks, 3 month and 6 months following their quit date, respectively.

Intervention: Financial Incentives (Behavioral)

Enhanced Usual Care plus Financial Incentives plus Mobile Health Application

Active Comparator

Participants receive all aspects of Arm 3 plus an intervention to promote episodic future thinking (EFT), called FutureMe. EFT has been shown to reliably reduce discounting of the future. Patients will practice using EFT cues to envision the "future is now" between the time of enrollment and the quit date, and will then receive cues from the quit date through the end of the intervention period, 6 months later, unless they ask to stop receiving cues sooner.

Intervention: Removal of Financial Barriers (Behavioral)

Enhanced Usual Care plus Financial Incentives plus Mobile Health Application

Active Comparator

Participants receive all aspects of Arm 3 plus an intervention to promote episodic future thinking (EFT), called FutureMe. EFT has been shown to reliably reduce discounting of the future. Patients will practice using EFT cues to envision the "future is now" between the time of enrollment and the quit date, and will then receive cues from the quit date through the end of the intervention period, 6 months later, unless they ask to stop receiving cues sooner.

Intervention: Financial Incentives (Behavioral)

Enhanced Usual Care plus Financial Incentives plus Mobile Health Application

Active Comparator

Participants receive all aspects of Arm 3 plus an intervention to promote episodic future thinking (EFT), called FutureMe. EFT has been shown to reliably reduce discounting of the future. Patients will practice using EFT cues to envision the "future is now" between the time of enrollment and the quit date, and will then receive cues from the quit date through the end of the intervention period, 6 months later, unless they ask to stop receiving cues sooner.

Intervention: Mobile Health Application (Behavioral)

Outcomes

Primary Outcomes

Biochemically Confirmed Smoking Abstinence Sustained for 6 Months

Time Frame: 6 months

The primary outcome measure is sustained abstinence for 6 months, and will require self-report of smoking cessation followed by biochemical confirmation at 2 weeks, 3, and 6 months.

Secondary Outcomes

  • Quit Status (Biochemically Confirmed)(2 weeks, 3 months, 12 months)
  • Health-related Quality of Life(Baseline)
  • Perceived Barriers to Cessation(Baseline)
  • Self-efficacy Related to Cessation Efforts(Baseline)
  • Motivation to Quit(Baseline)
  • Motivation to Quit(6 months)
  • Temporal ("Delay") Discounting(Baseline)
  • Health-related Quality of Life(6 months)
  • Perceived Barriers to Cessation(6 months)
  • Self-efficacy Related to Cessation Efforts(6 months)
  • Temporal ("Delay") Discounting(6 months)
  • Health-related Quality of Life(12 months)
  • Perceived Barriers to Cessation(12 months)
  • Self-efficacy Related to Cessation Efforts(12 months)
  • Motivation to Quit(12 months)
  • Temporal ("Delay") Discounting(12 months)
  • Self-report Cigarette Abstinence(2 weeks, 3 months, 6 months, 12 months)
  • Self-report Other Tobacco Abstinence(2 weeks, 3 months, 6 months, 12 months)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (5)

Loading locations...

Similar Trials